Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Heidelberg Pharma AGWBO:HPHA 10 Quick Ratio is 3.83 as of May. 2026, which is 67% above its 10-year median of 2.30. GuruFocus rates WBO:HPHA with a GF Score™ of 10/100 and a GF Value™ of €0.94 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Heidelberg Pharma AG ranks worse than 75.34% on this metric.
Heidelberg Pharma AG has a quick ratio of 3.83. It generally indicates good short-term financial strength.
The historical rank and industry rank for Heidelberg Pharma AG's Quick Ratio or its related term are showing as below:
WBO:HPHA'
s Quick Ratio Range Over the Past 10 Years
Min: 0.16 Med: 2.3 Max: 8.09
Current: 1.33
During the past 13 years, Heidelberg Pharma AG's highest Quick Ratio was 8.09. The lowest was 0.16. And the median was 2.30.
WBO:HPHA's Quick Ratio is ranked worse than 75.34% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs WBO:HPHA: 1.33
Heidelberg Pharma AG (WBO:HPHA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Heidelberg Pharma AG Quick Ratio Related Terms
Heidelberg Pharma AG Quick Ratio Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:HPHA vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Heidelberg Pharma AG's Quick Ratio for the fiscal year that ended in Nov. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heidelberg Pharma AG (WBO:HPHA) has a Quick Ratio of 3.83 as of May. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Heidelberg Pharma AG and its competitors. This is 67% above median its historical median of 2.30. Over the past decade, Heidelberg Pharma AG's Quick Ratio has ranged from 0.16 to 8.09. According to the industry distribution chart, Heidelberg Pharma AG ranks #1063 out of 1411 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Heidelberg Pharma AG's Quick Ratio too high?
Heidelberg Pharma AG's current Quick Ratio of 3.83 is 67% above median its 10-year median of 2.30. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 8.09. The Biotechnology industry median Quick Ratio is 3.59. Heidelberg Pharma AG's value of 3.83 is 6.7% above this industry median. Based on the distribution chart, Heidelberg Pharma AG ranks #1063 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #1063 out of 1411 companies for Quick Ratio. This places Heidelberg Pharma AG in the lower half of its industry. The industry median Quick Ratio is 3.59. Heidelberg Pharma AG's value of 3.83 is 6.7% above this benchmark. Historically, Heidelberg Pharma AG's own Quick Ratio has ranged from 0.16 to 8.09 over the past decade. While the company's 10-year median is 2.30 vs. the industry median of 3.59, Heidelberg Pharma AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Heidelberg Pharma AG's current Quick Ratio of 3.83 is 6.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Heidelberg Pharma AG and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Heidelberg Pharma AG's current Quick Ratio is 3.83, which is 67% above median its own 10-year median of 2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (WBO:HPHA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.94, compared to a current price of €2.55 — trading 171.3% above its estimated fair value. The current Quick Ratio is 3.83, which is 67% above median its 10-year median of 2.30 and 6.7% above the Biotechnology industry median of 3.59. Heidelberg Pharma AG's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Heidelberg Pharma AG (WBO:HPHA), the current Quick Ratio is 3.83 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (WBO:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be overvalued.
The current stock price of €2.55 is trading 171.3% above its estimated GF Value™ of €0.94.
GuruFocus considers Heidelberg Pharma AG to be Significantly Overvalued.
Key valuation signals for WBO:HPHA:
Quick Ratio: 3.83 (67% above median its 10-year median of 2.30)
GF Value™: €0.94 vs. price of €2.55 (171.3% above fair value)
Industry Position: 6.7% above the Biotechnology median (#1063 of 1411)
No single metric tells the full story. See the WBO:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
10GF Score
Get the complete analysis for WBO:HPHA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:HPHA has been successfully added to your 
